Affect in Parkinson's disease: validation of the two-factor approach.
Identifieur interne : 001C07 ( Main/Merge ); précédent : 001C06; suivant : 001C08Affect in Parkinson's disease: validation of the two-factor approach.
Auteurs : Emmanuelle Pourcher [Canada] ; Sophie Rémillard ; Henri CohenSource :
- Journal of the neurological sciences [ 1878-5883 ] ; 2010.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Depression (diagnosis), Depression (drug therapy), Depression (etiology), Dopamine (metabolism), Female, Humans, Hyperkinesis (chemically induced), Hypokinesia (chemically induced), Levodopa (adverse effects), Levodopa (therapeutic use), Longitudinal Studies, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Psychiatric Status Rating Scales, Reproducibility of Results, Serotonin (metabolism), Time Factors.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , metabolism : Dopamine, Serotonin.
- chemical , therapeutic use : Antidepressive Agents, Antiparkinson Agents, Levodopa.
- chemically induced : Hyperkinesis, Hypokinesia.
- complications : Parkinson Disease.
- diagnosis : Depression.
- drug therapy : Depression, Parkinson Disease.
- etiology : Depression.
- Aged, Female, Humans, Longitudinal Studies, Male, Middle Aged, Psychiatric Status Rating Scales, Reproducibility of Results, Time Factors.
Abstract
Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinetic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.
DOI: 10.1016/j.jns.2009.08.048
PubMed: 19747694
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D76
- to stream PubMed, to step Curation: 000D76
- to stream PubMed, to step Checkpoint: 000D76
- to stream Ncbi, to step Merge: 000B45
- to stream Ncbi, to step Curation: 000B45
- to stream Ncbi, to step Checkpoint: 000B45
Links to Exploration step
pubmed:19747694Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Affect in Parkinson's disease: validation of the two-factor approach.</title>
<author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
<affiliation wicri:level="1"><nlm:affiliation>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec, Canada. psa@riq.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Rémillard">Sophie Rémillard</name>
</author>
<author><name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:19747694</idno>
<idno type="pmid">19747694</idno>
<idno type="doi">10.1016/j.jns.2009.08.048</idno>
<idno type="wicri:Area/PubMed/Corpus">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D76</idno>
<idno type="wicri:Area/PubMed/Curation">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D76</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D76</idno>
<idno type="wicri:Area/Ncbi/Merge">000B45</idno>
<idno type="wicri:Area/Ncbi/Curation">000B45</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B45</idno>
<idno type="wicri:Area/Main/Merge">001C07</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Affect in Parkinson's disease: validation of the two-factor approach.</title>
<author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
<affiliation wicri:level="1"><nlm:affiliation>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec, Canada. psa@riq.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Remillard, Sophie" sort="Remillard, Sophie" uniqKey="Remillard S" first="Sophie" last="Rémillard">Sophie Rémillard</name>
</author>
<author><name sortKey="Cohen, Henri" sort="Cohen, Henri" uniqKey="Cohen H" first="Henri" last="Cohen">Henri Cohen</name>
</author>
</analytic>
<series><title level="j">Journal of the neurological sciences</title>
<idno type="eISSN">1878-5883</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Depression (diagnosis)</term>
<term>Depression (drug therapy)</term>
<term>Depression (etiology)</term>
<term>Dopamine (metabolism)</term>
<term>Female</term>
<term>Humans</term>
<term>Hyperkinesis (chemically induced)</term>
<term>Hypokinesia (chemically induced)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Psychiatric Status Rating Scales</term>
<term>Reproducibility of Results</term>
<term>Serotonin (metabolism)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term>
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hyperkinesis</term>
<term>Hypokinesia</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Depression</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
<term>Reproducibility of Results</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Depression in Idiopathic Parkinson's disease (IPD) is frequent, difficult to recognize, under managed and has a profound impact on quality of life. Current categorization of diagnosis in psychiatry poorly applies to the protean manifestations of mood disorders presented by parkinsonian patients. In this study we have chosen to dissect the state of depressive mood as assessed with the Beck Depression Inventory (BDI) at different points in time of pharmacological interventions using a dimensional approach. The 21 items of the BDI were classified in two new categories or factors: hyperkinetic and hypokinetic. The hyperkinetic factor included all items related to unbalanced intrusions of negative feelings and ideas, as well as to behavioral hyperactivity. The hypokinetic factor included all items related to loss of drive for appetitive behaviors and loss of mental and physical energy. The objectives were to (1) compare different pharmacological treatments on the two-factor approach in PD depression, (2) determine the influence of levodopa therapy on the two-factor approach, and (3) explore the two-factor approach in placebo conditions. Three sets of analyses using the hypo/hyperkinetic dichotomy favour a neurobiological dissociation of these factors in response to pharmacological intervention: symptoms of the hyperkinetic factor are responsive to serotonergic drugs while those of the hypokinetic one are not and may even show deterioration under SSRIs. In contrast, the hypokinetic factor is responsive to dopaminergic drugs and may show deterioration under serotonergic drugs. Furthermore, the two factors seem to transiently dissociate on placebo intervention aiming at correcting either mood or motor status. The dimensional approach to depression symptomatology may thus be of heuristic value in probing aminergic modulation of mood in IPD and establishing new correlations between affective and motor symptoms.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001C07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:19747694 |texte= Affect in Parkinson's disease: validation of the two-factor approach. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:19747694" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |